We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Non-Invasive Process Determines Blood Glucose Levels Without Sample

By LabMedica International staff writers
Posted on 03 Oct 2022
Print article
Image: New non-invasive blood glucose monitoring process could put an end to painful pricks to draw blood (Photo courtesy of Pexels)
Image: New non-invasive blood glucose monitoring process could put an end to painful pricks to draw blood (Photo courtesy of Pexels)

Diabetics are often required to prick their finger several times a day to draw blood and check their glucose levels using an electronic monitor. Researchers have been working on working on improving the glucose monitoring process for the millions of people around the world affected by diabetes by making it less invasive and painful. Now, a team of researchers has created a non-invasive process that can identify the exact value of blood glucose with 90% accuracy without taking a blood sample.

The GlucoCheck process developed by researchers at Kennesaw State University (Kennesaw, GA, USA) uses light shone through human tissue, in either the ear or finger, and a small camera to capture images on the other side. The team then uses a model to study the amount of light absorption in those images to determine blood glucose concentration. The team has filed a provisional patent application with the U.S. Patent and Trademark Office to protect the process they have created. The researchers have tested the process on nearly 50 people so far, but before filing a full patent next summer, they will assess how the process works on people with a range of skin pigmentations and skin thickness. The team has already created a mobile phone application and is working on connecting GlucoCheck to Amazon’s virtual assistant, Alexa.

“Our pilot study was very successful. We are excited about how this device will help people with diabetes, which affects about one in every 10 people in the United States,” said Maria Valero, assistant professor of information technology in Kennesaw State’s College of Computing and Software Engineering (CCSE). “The way we gather and output the data is novel, and we will continue to work on ways to improve the glucose estimation model.”

Related Links:
Kennesaw State University 

Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Chlamydia Trachomatis Assay
Chlamydia Trachomatis IgG
New
Luteinizing Hormone Assay
DRG LH-Serum ELISA Kit

Print article

Channels

Clinical Chemistry

view channel
Image: Professor Nicole Strittmatter (left) and first author Wei Chen stand in front of the mass spectrometer with a tissue sample (Photo courtesy of Robert Reich/TUM)

Mass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication

Speed and accuracy are essential when diagnosing diseases. Traditionally, diagnosing bacterial infections involves the labor-intensive process of isolating pathogens and cultivating bacterial cultures,... Read more

Molecular Diagnostics

view channel
Image: Macrophages infected with mycobacterium tuberculosis (Photo courtesy of MIT)

New Molecular Label to Help Develop Simpler and Faster Tuberculosis Tests

Tuberculosis (TB), the deadliest infectious disease globally, is responsible for infecting an estimated 10 million people each year and causing over 1 million deaths annually. While chest X-rays and molecular... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.